NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin…